JERUSALEM, Israel, December 21 OramedPharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developerof alternative drug delivery systems, announced today that Dr Roy Eldor willpresent an overview of the clinical development of Oramed's Oral Insulincapsule. Dr. Eldor is the principal investigator for all of Oramed's clinicaltrials conducted at Hadassah Medical Center. He is a physician in theDiabetes Unit and Endocrinology Department of Hadassah Medical Center.
The conference will take place at the Wohl Center, Bar Ilan University,in Ramat Gan, Israel on December 21-23. Dr Eldor's presentation will be givenon December 22 at 4:10 PM. He will be highlighting all of the clinical workthat Oramed has completed to date, ranging from preclinical trials to itscurrent Phase 2b trial.
"Oramed is honored to have been invited to present at this very importantconference to share the clinical development of its Oral Insulin Capsule withthe scientific community" says Dr Roy Eldor.
About the Conference:
The Conference will start to focus on the translation of "cutting edge"diabetes research into practical clinical care, with a particular emphasis onthe organization and delivery of care in different health systems. Updatesand overviews will be given by invited speakers from around the world,together with workshop and debate sessions and submitted oral and posterpresentations.
For More information, please visit http://www.diabetescenter.org.il
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oraldelivery solutions for drugs and vaccines presently delivered via injection.Oramed is seeking to revolutionize the treatment of diabetes through itspatented flagship product, an orally ingestible insulin capsule currently inphase 2 clinical trials. Established in 2006, Oramed's technology is based onover 25 years of research by top research scientists at Jerusalem's HadassahMedical Center. The Company's corporate and R&D headquarters are based inJerusalem.
For more information, please visit http://www.oramed.com.
Some of the statements contained in this press release areforward-looking statements which involve known and unknown risks,uncertainties and other factors which may cause the actual results,performance or achievements of the company, or industry results, to bematerially different from any future results, performance or achievementsexpressed or implied by such forward looking statements, including the risksand uncertainties related to the progress, timing, cost, and results ofclinical trials and product development programs; difficulties or delays inobtaining regulatory approval for our product candidates; competition fromother pharmaceutical or biotechnology companies; and the company's ability toobtain additional funding required to conduct its research, development andcommercialization activities. Please refer to the company's filings with theSecurities and Exchange Commission for a comprehensive list of risk factorsthat could cause actual results, performance or achievements of the companyto differ materially from those expressed or implied in such forward lookingstatements. The company undertakes no obligation to update or revise anyforward-looking statements.Company and Investor Relations Contacts: Oramed Pharmaceuticals Tara Horn USA: +1-646-240-4193 Int'l: +972-54-334-318 Office: +972-2-566-0001 Email: firstname.lastname@example.org
SOURCE Oramed Pharmaceuticals Inc.